Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog

Xenobiotica

Volumn 26, Issue 3, 1996, Pages 321-332

  Hosoe, K ^a   Mae, T ^a   Yamashita, K ^a   Fujii, K ^a   Yamane, T ^a   Hidaka, T ^a   Ohashi, T ^a  

^a KANEKA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; RIFALAZIL; RIFAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG IDENTIFICATION; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; URINE;

ANIMALIA; CANIS FAMILIARIS; CORYNEBACTERINEAE;

EID: 0029872462     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046711     Document Type: Article

References (14)

1. BERMUDEZ, L. E., KOLONOSKI, P., YOUNG, L. S., and INDERLIED, C. B., 1994, Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrobial Agents and Chemotherapy, 38, 1844-1848.
2. EMORI, M., SAITO, H., SATO, K., TOMIOKA, H., SETOGAWA, T., and HIDAKA, T., 1993, Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrobial Agents and Chemotherapy, 37, 722-728.
3. FUJII, K., TSUJI, A., MIYAZAKI, S., YAMAGUCHI, K., and GOTO, S., 1994, In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrobial Agents and Chemotherapy, 38, 1118-1122.
4. INDERLIED, C. B., YOUNG, L. S., and YAMAHA, J. K., 1987, Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimicrobial agents by various methods. Antimicrobial Agents and Chemotherapy, 31, 1697-1702.
5. INDERLIED, C. B., BARBARA-BURNHAM, L., WU, M., YOUNG, L. S., and BERMUDEZ, L. E., 1994, Activity of the benzoxazinorifamycin KRM-1648 and ethambutol against Mycobacterium avium complex in vitro and macrophages. Antimicrobial Agents and Chemotherapy, 38, 1838-1843.
6. KLEMENS, S. P., GROSSI, M. A., and CYNAMON, M. H., 1994, Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy, 38, 2245-2248.
7. KUZE, F., YAMAMOTO, T., AMITANI, R., and SUZUKI, K., 1991, In vitro activities of new rifamycin derivatives against mycobacteria. Kekkaku, 66, 7-12.
8. LUNA-HERRERA, J., REDDY, M. V., and GANGADHARAM, P. R. J., 1995, In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy, 39, 440-444.
9. SAITO, H., TOMIOKA, H., SATO, K., EMORI, M., YAMANE, T., YAMASHITA, K., HOSOE, K., and HIDAKA, T., 1991, In Vitro antimycobacterial activities of newly synthesized benzoxazinofifamycin. Antimicrobial Agents and Chemotherapy, 35, 542-547.
10. TILTON, R. C., 1984, Antimicrobial susceptibility tests. In Antimicrobial Therapy, edited by A. J. Ristuccia and B. A. Cunha (New York: Raven), pp. 137-145.
11. TOMIOKA, H., SAITO, H., SATO, K., YAMANE, T., YAMASHITA, K., HOSOE, K., FUJII, K., and HIDAKA, T., 1992. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy, 36, 387-393.
12. TOMIOKA, H., SAITO, H., FUJII, K., SATO, K., and HIDAKA, T., 1993, In vitro antimicrobial activity benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex determined by the radiometric method. Antimicrobial Agents and Chemotherapy, 37, 67-70.
13. YAMAMOTO, T., AMITANI, R., KUZE, F., and SUZUKI, K., 1990, In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex. Kekkaku, 65, 805-810.
14. YAMANE, T., HASHIZUME, T., YAMASHITA, K., KONOSHI, K., HOSOE, K., HIDAKA, T., WATANABE, K., KAWAHARADA, H., YAMAMOTO, T., and KUZE, F., 1993, Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chemical and Pharmaceutical Bulletin, 41, 148-155.